Prof. MEHMET ALİ NAHİT ŞENDUR

Publication Network

Published journal articles indexed by SCI, SSCI, and AHCI

Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Cicin I., Karadurmus N., BİLİCİ A., Bahsi T., ŞENDUR M. A. N., Demirci U., et al.

Future oncology (London, England) , vol.20, no.15, pp.1031-1045, 2024 (SCI-Expanded)

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., Karadurmuş N., Ökten İ. N., TÜRK H. M., Urakçı Z., Arslan Ç., et al.

Journal of Oncology Pharmacy Practice , 2024 (SCI-Expanded)

Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Kaplan M. A., ŞENDUR M. A. N., Cangır A. K., Fırat P., Göker E., Kılıçkap S., et al.

Current Problems in Cancer , vol.47, no.6, 2023 (SCI-Expanded)

Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskeletal events?

Yağar H., Aytekin M. N., sener dede D., Sendur M., öztürk r., yalcin b.

Joint Diseases and Related Surgery , vol.35, no.1, pp.105-111, 2023 (SCI-Expanded)

Tamoxifen related chorioretinal structural changes

Erbahçeci Timur İ. E., Açıkgöz V., Uğurlu N., Yalçın B., ŞENDUR M. A. N., Hızal M., et al.

Cutaneous and Ocular Toxicology , vol.42, no.3, pp.109-117, 2023 (SCI-Expanded)

Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Yekedüz E., ÖZBAY M. F., Çağlayan D., YILDIRIM A., Erol C., YILDIRIM H. Ç., et al.

European Journal of Clinical Pharmacology , vol.78, no.12, pp.1973-1979, 2022 (SCI-Expanded)

Adjuvant immunotherapy for renal cell carcinoma

ŞENDUR M. A. N.

The Lancet. Oncology , vol.23, no.9, pp.1110-1111, 2022 (SCI-Expanded)

Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., et al.

Tumori , vol.107, no.5, pp.416-423, 2021 (SCI-Expanded) Sustainable Development

The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement

Bilgin B., ŞENDUR M. A. N., Yücel Ş., Hizal M., Güner G., Akyürek N., et al.

Journal of Cancer Research and Clinical Oncology , vol.147, no.9, pp.2637-2643, 2021 (SCI-Expanded) Sustainable Development

Can the host immune response against SARS-CoV2 also cause an anticancer effect?

KAHRAMAN S., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B.

Medical Oncology , vol.38, no.8, 2021 (SCI-Expanded)

“Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?

Karacin C., Acar R., Bal O., Eren T., ŞENDUR M. A. N., Acikgoz Y., et al.

Supportive Care in Cancer , vol.29, no.8, pp.4587-4593, 2021 (SCI-Expanded)

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., ŞENDUR M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.

Journal of Cancer Research and Clinical Oncology , vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded) Sustainable Development

A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint

HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.

Current Medical Research and Opinion , vol.36, no.4, pp.625-635, 2020 (SCI-Expanded)

Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?

HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., Dede D., YALÇIN B.

Journal of B.U.ON. , vol.24, no.4, pp.1367-1370, 2019 (SCI-Expanded)

The current status of adjuvant treatment for high-risk renal cell carcinoma

HIZAL M., ŞENDUR M. A. N., Bilgin B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.

FUTURE ONCOLOGY , vol.13, no.23, pp.2017-2020, 2017 (SCI-Expanded)

Targeted therapies in gastric cancer and future perspectives

Yazici O., ŞENDUR M. A. N., Ozdemir N., AKSOY S.

WORLD JOURNAL OF GASTROENTEROLOGY , vol.22, no.2, pp.471-489, 2016 (SCI-Expanded) Sustainable Development

A comprehensive review of denosumab for bone metastasis in patients with solid tumors

Gul G., ŞENDUR M. A. N., AKSOY S., Sever A. R., Altundag K.

CURRENT MEDICAL RESEARCH AND OPINION , vol.32, no.1, pp.133-145, 2016 (SCI-Expanded)

Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N., Yazici O., Sever A. R., et al.

JOURNAL OF BUON , vol.21, no.1, pp.27-34, 2016 (SCI-Expanded) Sustainable Development

A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience

Yazilitas D., Ozdemir N., Hocazade C., Bozkaya Y., Yazici O., ŞENDUR M. A. N., et al.

JOURNAL OF BUON , vol.20, no.6, pp.1526-1533, 2015 (SCI-Expanded)

Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature

Ulas A., SILAY K., Akinci S., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., et al.

ONCOLOGY LETTERS , vol.10, no.4, pp.2223-2226, 2015 (SCI-Expanded)

Do Statins Really Improve Colorectal Cancer-Specific Mortality?

ŞENDUR M. A. N., AKSOY S., Yalcin B.

JOURNAL OF CLINICAL ONCOLOGY , vol.33, no.7, pp.811, 2015 (SCI-Expanded) Sustainable Development

Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer

ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., ŞENER DEDE D., Ulas A., et al.

FUTURE ONCOLOGY , vol.11, no.8, pp.1141-1143, 2015 (SCI-Expanded) Sustainable Development

Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

ŞENDUR M. A. N., AKSOY S., AKINCI M. B., Ozdemir N., ŞENER DEDE D., Altundag K., et al.

FUTURE ONCOLOGY , vol.11, no.6, pp.905-907, 2015 (SCI-Expanded) Sustainable Development

Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab

ŞENDUR M. A. N., AKSOY S., Altundag K.

FUTURE ONCOLOGY , vol.11, no.1, pp.13-15, 2015 (SCI-Expanded)

Current Treatment Options for Metastatic Pancreatic Adenocarcinoma

ŞENDUR M. A. N., Yazici O., Ozdemir N. Y., AKSOY S.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.25, no.4, pp.263-274, 2015 (SCI-Expanded)

Resistance to Androgen-Pathway Drugs in Prostate Cancer

ŞENDUR M. A. N., AKINCI M. B., YALÇIN B.

NEW ENGLAND JOURNAL OF MEDICINE , vol.371, no.23, pp.2233, 2014 (SCI-Expanded) Sustainable Development

The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., Zengin N., Altundag K.

CURRENT MEDICAL RESEARCH AND OPINION , vol.30, no.12, pp.2535-2542, 2014 (SCI-Expanded) Sustainable Development

Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia

Acikgoz Y., ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N.

MEDICAL ONCOLOGY , vol.31, no.9, 2014 (SCI-Expanded)

Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

ŞENDUR M. A. N., Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinci A. S., et al.

MEDICAL ONCOLOGY , vol.31, no.9, 2014 (SCI-Expanded) Sustainable Development

Impact of Acetylsalicylic Acid on the Clinicopathological Characteristics and Prognosis of Patients with Invasive Breast Cancer

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Zengin N., Altundag K.

BREAST CARE , vol.9, no.4, pp.261-266, 2014 (SCI-Expanded)

Lung Cancer Screening: A Comprehensive Review of the Literature with Detailed Data

Acikgoz Y., ŞENDUR M. A. N., Ozdemir N. Y., AKSOY S., Zengin N.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.24, no.4, pp.270-278, 2014 (SCI-Expanded)

Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers

Cihan S., KÜÇÜKÖNER M., Ozdemir N., DANE F., ŞENDUR M. A. N., Yazilitas D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.13, pp.5337-5341, 2014 (SCI-Expanded)

Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded)

Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients

Ozdemir N., AKSOY S., ŞENDUR M. A. N., AKINCI M. B., Yazici O., Budakoglu B., et al.

Journal of B.U.ON. , vol.18, no.4, pp.831-837, 2013 (SCI-Expanded)

Does zoledronic acid have additive effect on suppression of plasma estrogen levels?

ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., AKINCI M. B., ZENGİN N., Altundaǧ K.

Asian Pacific Journal of Cancer Prevention , vol.14, no.1, pp.607-608, 2013 (SCI-Expanded)

Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?

ŞENDUR M. A. N., Özdemir N. Y., AKINCI M. B., Uncu D., ZENGİN N., AKSOY S.

World Journal of Gastroenterology , vol.19, no.1, pp.144-146, 2013 (SCI-Expanded)

New treatment trends in small cell carcinoma of the urinary bladder

ŞENDUR M. A. N., AKSOY S., Yazici O., AKINCI M. B., Ozdemir N., ZENGİN N.

Journal of B.U.ON. , vol.17, no.4, pp.799-800, 2012 (SCI-Expanded)

Articles Published in Other Journals

Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials

Rauthan A., Jain A., Singh M., ŞENDUR M. A. N.

Oncology and Therapy , vol.12, no.3, pp.395-418, 2024 (ESCI)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer

Sekmek S., Ucar G., Karahan I., Bayram D., Aktürk Esen S., Seven I., et al.

African Journal of Urology , vol.29, no.1, 2023 (ESCI)

RETRACTED ARTICLE: Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors

Guler F., Yuksel N., KAHRAMAN S., ŞENDUR M. A. N.

Oncology and Therapy , vol.11, no.3, pp.391-396, 2023 (ESCI)

Immunotherapy for Lung Cancer

Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., et al.

Journal of Oncological Science , vol.9, no.2, pp.97-111, 2023 (Scopus)

Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., et al.

Journal of Gastrointestinal Cancer , vol.53, no.2, pp.282-288, 2022 (ESCI) Sustainable Development

The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer

Hizal M., ŞENDUR M. A. N., Bilgin B., Karci Güner E., AKINCI M. B., Ergün Y., et al.

Journal of Oncological Science , vol.8, no.2, pp.69-75, 2022 (Scopus)

Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination

Sümbül A. T., YALÇIN S. S., ÖZET A., ÜNAL S., DİZDAR Ö., Akbulut H., et al.

Journal of Oncological Science , vol.7, no.1, pp.1-6, 2021 (Scopus)

The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer Küçük hücreli dışı akciğer kanserinde yüksek pd-l1 düzeyi ile ilişkili klinikopatolojik faktörlerin ve periferik kan parametrelerinin belirlenmesi

Bilgin B., HIZAL M., Yücel Ş., ŞENDUR M. A. N., AKYÜREK N., AKINCI M. B., et al.

Tuberkuloz ve Toraks , vol.68, no.2, pp.118-125, 2020 (ESCI)

Prognostic importance of Albumin globulin ratio in small cell lung cancer Albümin Globulin Oraninin Küçük Hücreli Akciǧer Kanserinde Prognostik Önemi

BİLGİN B., ŞENDUR M. A. N., yücel Ş., HIZAL M., YALÇIN B.

Ankara Medical Journal , vol.18, no.4, pp.729-735, 2019 (Scopus)

Experience from Turkish centers participating in the Early Access Program (EAP):Preliminary real-world safety data of nivolumab (nivo) combined withipilimumab (ipi) in pre-treated advanced melanoma patients

KARADURMUŞ N., ŞENDUR M. A. N., KARACA Ş. B., ÖLMEZ Ö. F., HACIBEKİROĞLU İ., COŞKUN H. Ş., et al.

journal of oncological scinece , 2019 (Peer-Reviewed Journal)

Evaluation of dynamic serum thiol-disulphide homeostasis in colorectal cancer

BİLGİN B., ŞENDUR M. A. N., HIZAL M., kandil ulutaş s., yaman s., AKINCI M. B., et al.

Journal of Oncological Sciences , 2019 (Peer-Reviewed Journal) Sustainable Development

Hyperthermia and radiotherapy combination for locoregional recurrences of breast cancer: a review

Arslan S. A., Ozdemir N., ŞENDUR M. A. N., Eren T., Ozturk H. F., Aral I. P., et al.

BREAST CANCER MANAGEMENT , vol.6, no.4, pp.117-126, 2017 (ESCI) Sustainable Development

Metastatic anal cloacogenic cell carcinoma misdiagnosed as urothelial carcinoma with long survival

BİLGİN B., YALÇIN B., ŞENDUR M. A. N., AĞAÇKIRAN Y.

Journal of Oncological Sciences , vol.3, no.2, pp.87-88, 2017 (Peer-Reviewed Journal)

Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları Tek Merkez Deneyimi Demographic Characteristics and Treatment Outcomes of Patients with Renal Cell Cancer Single Center Experience

ulaş a., BİLGİN B., ŞENER DEDE D., köş t., AKINCI M. B., ŞENDUR M. A. N., et al.

Ankara Medical Journal , 2016 (Peer-Reviewed Journal) Sustainable Development

Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey

Ulas A., Silay K., Akinci S., Dede D., AKINCI M. B., ŞENDUR M. A. N., et al.

Asian Pacific Journal of Cancer Prevention , vol.16, no.5, pp.1699-1705, 2015 (Scopus)

TÜRKİYE DE ONKOLOJİ HASTALARININ BİYOPSİKOSOSYAL VE KOZMİK İHTIYAÇLARI

SILAY K., AKINCI M. B., ARİFE U., AKINCI S., ŞENDUR M. A. N., ŞENER DEDE D., et al.

Turkiye Klinikleri Journal of Psychiatry Special Topics , vol.7, no.4, pp.1-4, 2014 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

A case of hypophysitis with panhypopituitarism after the use of the immune check point inhibitor pembrolizumab

Çopuroğlu E., FAKI S., BAŞER H., ŞENDUR M. A. N., Kılıç A., TOPALOĞLU O., et al.

Endobridge 2021, 21 October 2021

EFFICACY AND SAFETY OF FOLFIRI/AFLIBERCEPT IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS (TOG STUDY)

EROL C., HIZAL M., BİLGETEKİN İ., akbaş s., ŞENER DEDE D., AKINCI M. B., et al.

10TH International Gastrointestinal Cancers Virtual Conference, Online, Turkey, 2 - 06 December 2020, pp.39-40

The incidence and prognostıc significance of sarcopenia in advanced gastric cancer patients

GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., et al.

10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 2 - 06 December 2020

PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY) Cihan Erol1 , Mutlu Hızal2 , Irem Bilgetekin3 , Sinem Akbas4 , Duygu Bayir Garbioglu5 , Jamshid Hamdard6 , Cagatay Arslan7 , Alper Sevinc8 , Ahmet Kucukarda9 , Dilek Gurgenyatagi10, Emre Cakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, Izzet Dogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17, Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut Emre Yildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, Halil Taskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25, Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, Abdullah Sakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1 , Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, Semra Paydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9 , Ahmet Bilici6 , Didem Sener Dede1 , Muhammed Bulent Akinci1 , Nil Molinas Mandel36, Berna Oksuzoglu3 , Dogan Uncu2 , Bulent Yalcin1 , Mehmet Artac12, Mehmet Ali Nahit Sendur1

EROL C., HIZAL M., BİLGETEKİN İ., akbaş s., ÇİÇİN İ., ŞENER DEDE D., et al.

10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

The investigation of the related factors that affected targeted therapy outcome in metastatic colon cancer

TUTUM Ş., BİLGİN B., HIZAL M., AKINCI M. B., YALÇIN B., ŞENDUR M. A. N.

10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 02 December 2020

THE INCIDENCE AND PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN ADVANCED GASTRIC CANCER PATIENTS

GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., et al.

10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

Malign Glial Tümörlerin Klinikopatolojik Özellikleri ve Sağkalim Verilerinin İncelenmesi

asan f. b., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., et al.

4. Uluslararası Hipokrat Tıp ve Sağlık Bilimleri Kongresi 25-26 Eylül 2020 Antalya, Türkiye, Antalya, Turkey, 25 September 2020, pp.925-932

MALİGN GLİAL TÜMÖRLERİN KLİNİKOPATOLOJİK ÖZELLİKLERİ VE SAĞKALIM VERİLERİNİN İNCELENMESİ

Aşan B., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., et al.

4th İnternational Hippocrates Congress on Medical and Health Science, Turkey, 25 - 16 September 2020

Current Treatment Options in 2nd line Gastric Cancer and Ramucirumab

KARADURMUŞ N., ŞENDUR M. A. N.

9th Internatıonal Gastrointestinal Cancer Conference, 6 - 08 December 2019 Sustainable Development

Give Her a long Life with Ribociclib in HR HER- aBC

ŞENDUR M. A. N.

6th congress of the mediterranean multidisciplinary oncology forum, 28 November - 01 December 2019

EFFİCACY AND SUCCESS OF AF ABLATİON İN CANCER PATİENTS

ATEŞ A. H., ŞENER Y. Z., ŞENDUR M. A. N., KILIÇKAP S., AYTEMİR K.

3.ULUSAL İMMİNOTERAPİ VE ONKOLOJİ KONGRESİ, Turkey, 30 October - 03 November 2019 Sustainable Development

Timing of ADT in the Era of Stampede and Latitude

ŞENDUR M. A. N.

World Urological Oncology Federation Symposium, 17 October 2019

GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.300 Sustainable Development

Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.

23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.185 Sustainable Development

GERIATRIK (≥75 YAŞ), KASTRASYON DIRENÇLI METASTATIK PROSTAT KANSERI (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUÇLARI- GERÇEK YAŞAM VERISI

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.

23. ULUSAL KANSER KONGRESİ - 2019, Turkey, 17 - 21 April 2019 Sustainable Development

Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

ALKAN A., Sevgen Güç Z., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.

23. Ulusal Kanser Kongresi - 2019, Turkey, 17 - 21 April 2019 Sustainable Development

Increasing role of genetics in the management of pancreatic cancer

ŞENDUR M. A. N.

8th International Gastrointestinal Cancers Conference, 7 - 09 December 2018 Sustainable Development

COMBINATION OF OxALIPLATIN, CAPECITABINE,t r a s t u z u m a b a n d c h e m o r a d io t h e r a p y INPATIENTS WITH GASTRIC CANCER

ABALI H., YALÇIN Ş., ÖNAL H. C., DANE F., ÇAKMAK ÖKSÜZOĞLU Ö. B., ÖZDEMİR N., et al.

8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018 Sustainable Development

Crizotinib efficacy in ALK-positive advanced stage non-small cell lung cancer patients: a real-world experience from Turkey.

KILIÇKAP S., Öztürk A., KARADURMUŞ N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.

IASLC 19th World Conference On Lung Cancer, Canada, 23 - 26 September 2018, vol.13, pp.1020

Neoadjuvant Treatment of Bladder Cancer

ŞENDUR M. A. N.

8th Eurasian Uro-oncology Congress, 28 June - 01 July 2018 Sustainable Development

Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey

Zengin G., Özyurt N., BEYPINAR İ., Çınkır H. Y., Bilgin B., GÜMÜŞAY Ö., et al.

ASCO 2018, 1 - 05 June 2018, vol.36, pp.15551 Sustainable Development

Case report: management of a patient with malignant insulinoma

TOPALOĞLU O., ŞENDUR M. A. N., DUMLU E. G., YILDIRIM F., TAŞKALDIRAN I., SOYDAL Ç., et al.

20th European Congress of Endocrinology, 19 - 22 May 2018

Detection of pulmonary metastases with 18F-Fluorocholine PET/CT and treatment of refractory hypercalcemia with denosumab in a patient with long term parathyroid carcinoma

TOPALOĞLU O., ŞENDUR M. A. N., DUMLU E. G., YILDIRIM F., TAŞKALDIRAN I., SOYDAL Ç., et al.

20th European Congress of Endocrinology, 19 - 22 May 2018

Independent prognostic value of inflammation in metastatic pancreatic cancer.

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., KÖKSOY E. B., DEMİRCİ N. S., ŞENDUR M. A. N., DEDE İ., et al.

JOURNAL OF CLINICAL ONCOLOGY, 1 - 05 June 2018, vol.36 Sustainable Development

Metastatik Pankreas Kanserinde 2. Basamak Tedavilerin Etkinliği

ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018 Sustainable Development

Metastatik Pankreas Kanserinde İkinci Basamak Tedavi Öncesi Prognostik Belirteçlerin Saptanması

BİLGİN B., ŞENDUR M. A. N., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018 Sustainable Development

The Role of Dynamic Serum Thiol-Disulphide Homeostasis in Metastatic Gastric Cancer

BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., DEDE D. Ş., YAMAN S., et al.

7TH INTERNATIONAL GASTROINTESTINAL CANCERS CONFERENCE, İstanbul, Turkey, 15 - 17 December 2017 Sustainable Development

Assesment of nutritional status in cancer patients

ŞENDUR M. A. N.

7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017 Sustainable Development

Evaluation of dynamic serum thiol disulphide homeostasis in colorectal cancer

BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., ŞENER DEDE D., Yaman S., et al.

7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017 Sustainable Development

Young oncologists asking experts answering

ŞENDUR M. A. N.

7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017

The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)

ŞENER DEDE D., TATLI DOĞAN H., ASAN F. B., GÜMÜŞKAYA ÖCAL B., AYIK Ş., ŞENDUR M. A. N., et al.

42nd ESMO Congress (ESMO 2017), 8 - 12 September 2017

Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction

ÖZDEMİR N., Toptaş Ş., ŞENDUR M. A. N., Yazıcı O., ÇAKMAK ÖKSÜZOĞLU Ö. B., SILAY K., et al.

42nd ESMO Congress (ESMO 2017), 8 - 12 September 2017

MEtaStatik vE nEoadjuvant tEdavi alan tRanSizyonEl HÜcREli MESanE kanSERindE HuMan EquiliBRativE nuclEoSidE tRanSpoRtER 1 (HEnt1) MolEkÜlÜnÜn pREdiktiF vE pRognoStik önEMinin dEğERlEndiRilMESi

ŞENER DEDE D., KILIÇARSLAN A., ULAŞ A., ŞENDUR M. A. N., YAMAN S., BİLGİN B., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017 Sustainable Development

2016 yIlInda tÜRkiyE kaynaklI onkolojik yayInlaR

ŞENDUR M. A. N., BİLGİN B., HIZAL M., ÖZDEMİR N., AKINCI M. B., ŞENER DEDE D., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017

ilERi EvRE koloREktal kanSERlERdE RdW-platElEt oRanInIn pRognoStik önEMi

BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017 Sustainable Development

t790M MutaSyonu pozitiF akciğER kanSERindE oSiMERtiniB diREnci; olgu SunuMu

BİLGİN B., ŞENDUR M. A. N., HIZAL M., ŞENER DEDE D., AKINCI M. B., SILAY K., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017 Sustainable Development

özEFaguS yaSSI HÜcREli kaRSinoMlaRda lokal tEdavi StRatEjilERi vE pRognoStik FaktöRlER

ÖZDEMİR N., DİKİCİ H. Z., ARSLAN S., YAZICI O., ŞENDUR M. A. N., SILAY K., et al.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017

FREQUENCY OF CHEMOTHERAPY INDUCED AMENORRHEA IN WOMEN WITH COLORECTALCANCER

ŞAHİN T., DİZDAR Ö., ÖZDEMİR N., ZENGİN N., ATEŞ Ö., ÇAKMAK ÖKSÜZOĞLU Ö. B., et al.

International Congress on Oncological Sciences, 27 September - 01 October 2017 Sustainable Development

Prognostıc importance red cell dısturbatıon wıdth to platelet ratio in advanced colorectal cancer

BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ S. K., et al.

6th international Gastrointestinal cancer conferance December 2016 Antalya, Turkey, 2 November - 06 December 2016 Sustainable Development

EFFECT OF RED CELL DISTURBATION WIDTH TO PLATELET RATIO ONDISEASE FREE SURVIVAL IN EARLY STAGE COLORECTAL CANCER

BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., Özdemir N. Y., et al.

6th InternatIonalGastroIntestInal CanCerConferenCe, 2 - 04 December 2016 Sustainable Development

THE NEUTROPHIL LYMPHOC YTE RATIO MAY HAVE PROGNOSTICEFFECT IN THE METASTATIC COLORECTAL CANCER

HIZAL M., BİLGİN B., ŞENDUR M. A. N., Dede D. Ş., AKINCI M. B., Kandil S. U., et al.

6th InternatIonalGastroIntestInal CanCerConferenCe, 2 - 04 December 2016 Sustainable Development

Local treatment strategies for esophageal SCC and prognostiıc factors

ÖZDEMİR N., Dikici H. Z., Arslan S. A., Yazıcı O., ŞENDUR M. A. N., Bal Ö., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016

Prognostic significance of reziduel tumor size after chemoradiotherapy for rectal adenocarcinoma

ÖZDEMİR N., Bozkaya Y., Aytaç arslan S., Yazıcı O., ŞENDUR M. A. N., ZENGİN N.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016

PROGNOSTIC IMPORTANCE RED CELL DISTURBATION WIDTH TOPLATELET RATIO IN ADVANCED COLORECTAL CANCER

BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., Yaman S., Kandil S. u., et al.

6th InternatIonalGastroIntestInal CanCerConferenCe, 2 - 04 December 2016 Sustainable Development

EFFECT OF THE RAS STATUS ON SURVIVAL IN ADVANCED COLON CANCER

BİLGİN B., HIZAL M., ŞENDUR M. A. N., Kandil S. U., Yaman S., AKINCI M. B., et al.

6th InternatIonal GastroIntestInal CanCer ConferenCe, 2 - 04 December 2016 Sustainable Development

THE PROGNOSTIC FACTORS IN STAGE 3 COLORECTAL CANCER PATIENTS

HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., Yaman S., et al.

6th InternatIonalGastroIntestInal CanCerConferenCe, 2 - 04 December 2016 Sustainable Development

Rituximab for primary extranodal lymphomas effectiveness

ÖZDEMİR N., Aytaç Arslan S., Hocazade C., Bozkaya Y., Yazıcı O., ŞENDUR M. A. N., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016

METASTATIC COLORECTAL CANCER SURVIVAL IS THERE A DIFFERENCEBETWEEN SYNCHRONOUS OR METACHRONOUS TUMORS

HIZAL M., BİLGİN B., ŞENDUR M. A. N., Dede D. Ş., AKINCI M. B., Yaman s., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

Tumor size in early stage N0 gastric carsinoma is it prognostic

ÖZDEMİR N., KOCABAŞ M., ARSLAN S., Yazıcı O., ŞENDUR M. A. N., Algın E., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016

ASSOSCIATION BETWEEN TUMOR LOCALISATION AND CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OF COLORECTAL CANCER

BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., yaman s., et al.

6,International gastrointestinal cancer confrence, 2 - 04 December 2016 Sustainable Development

Association between tumor localisation and clinicopathological characteristics and survival of colorectal cancer

BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., yaman S., et al.

th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

Local treatment stratejies for esophageal scc and prognostic factors

ÖZDEMİR N., dikici h., AYTAÇ ARSLAN S., yazıcı o., ŞENDUR M. A. N., bal ö., et al.

6th international gis conference, 02 December 2016

Gastric cancer with lung metastasis and concurrent miliary tuberculosis

HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., YALÇIN B.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

A rare case metastatic anal cloacogenic transitional cell carcinoma

BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., Yaman S., Ulutaş Kandil S., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016

Compare tumor features and survival in right sided and left sided early stage colorectal cancer

BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., ÖZDEMİR N., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

ASSESSMENT OF THE COST EFFECTIVENESS OF THE FIRST LINE TARGETED THERAPIES FOR ADVANCED COLON CANCER IN TURKEY

BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., ulutaş kandil s., yaman s., et al.

6,International gastrointestinal cancer confrence, 2 - 04 December 2016 Sustainable Development

Prognostic significance of rezidual tumor size after chemoradiotherapy for rectal adenocarcinoma

ÖZDEMİR N., bozkaya y., AYTAÇ ARSLAN S., yazıcı o., ŞENDUR M. A. N.

6th international gis conference, 2 - 04 December 2016

Effects of neutrophil lymphocyte ratio and platelet lymphocyte ratio on survival of non metastatic colorectal cancer

HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., Ulutaş Kandil S., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

Metastatic colorectal cancer survival İs there a difference between synchronous or metachronous tumors

HIZAL M., BİLGİN B., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., yaman s., et al.

6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016 Sustainable Development

Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancerM A Sendur1 S Aksoy2 N Ozdemir1 O Yazici3 M B Akıncı1 D S Dede1 B Yalçın1 N Zengin1 K Altundag2

ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., YAZICI O., AKINCI M. B., ŞENER DEDE D., et al.

ESMO, 7 - 11 November 2016 Sustainable Development

Association between tumor localisation andClinicopathologic characteristics and survival of colorectal cancer

BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., YAMAN S., et al.

6th international Gastrointestinal cancer conferance December 2016 Antalya, Turkey, 2 - 06 November 2016 Sustainable Development

Effect of red cell disturbatıon width to platelet ratio on dısease free survival in early stage colorectal cancer

BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., ÖZDEMİR N., et al.

6th international Gastrointestinal cancer conferance December 2016 Antalya, Turkey, 2 - 06 November 2016 Sustainable Development

Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer

Yazıcı O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.

41st ESMO Congress (ESMO 2016), 7 - 11 October 2016 Sustainable Development

Prognosti role of tumor location in stage 3 colorectal cancer patients received adjuvant chemotherapy

ÖZDEMİR N., AYTAÇ ARSLAN S., erdoğan k., yazıcı o., ŞENDUR M. A. N., bozkaya y., et al.

ESMO 2016, 7 - 11 October 2016 Sustainable Development

Efficacy of statin usage before diagnosis on clinico pathological characteristics and outcome of invasive breast cancer Annals of Oncology

ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., yazıcı o., YALÇIN B., ZENGİN N., et al.

41st ESMO Congress (ESMO 2016), 7 - 11 October 2016 Sustainable Development

Comparison of clinical outcomes in patents with early stage ER PR HER2 breast cancer patients with triple negatives

YAZICI O., ERDEM G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., DOĞAN M., et al.

2016 ASCO Annual Meeting, 3 - 07 June 2016 Sustainable Development

Adjuvant chemotherapy for esophageal scc

ÖZDEMİR N., AYTAÇ ARSLAN S., ŞENDUR M. A. N.

6th international gis conference, 2 - 04 December 2016

METASTATİK MALİGN MELANOMDA BİRİNCİ BASAMAK TEDAVİLERİN MALİYET ANALİZİ

BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., ULAŞ A., YAMAN S., et al.

6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016

METASTATİK KOLON KANSERİ HASTALARINDA BİRİNCİ BASAMAK HEDEFE YÖNELİK TEDAVİLERİN MALİYET ANALİZİ

BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ULAŞ A., YAMAN S., BAŞER S., et al.

6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016

A novel strategy for determining circulating tumour cells in lung cancer

ARKAN T. K., ÖZ B. E., ERSAN B., ERCAN E., ŞENDUR M. A. N., ALPARSLAN PINARLI F., et al.

10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, Germany, 19 - 21 March 2016

A novel strategy for determining circulating tumour cells in lungcancer

Arkan T. K., ÖZ B. E., Ersan B., Ercan E., ŞENDUR M. A. N., Alparslan Pınarlı F., et al.

10th ISMRC International Symposium on Minimal Residual Cancer Liquid Biopsy in Cancer Diagnostic and Treatment, Hamburg, Germany, 19 - 21 March 2016, pp.73

A novel strategy for determining circulating tumour cells in lung cancer

ARKAN T. K., ÖZ B. E., Bilgesu E., ERCAN E., ŞENDUR M. A. N., Alparslan Pınarlı F., et al.

10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, 19 - 21 March 2016

The effect of body mass index in patients with relapsed colorectal cancer

Yazıcı O., Yazılıtaş D., ÖZDEMİR N., Demirci N. S., Erdem G., Bozkaya Y., et al.

5th İnternational Gastrointestinal Cancers Conference, 4-6 December 2015, İstanbul-Turkey., 4 - 06 December 2015 Sustainable Development

Multiple Akciğer ve Kemik Metastazı Yapan Deri Eki Tümörü

KIRAN M. M., TATLI DOĞAN H., SÜNGÜ N., ŞENDUR M. A. N.

25.Ulusal Patoloji Kongresi, Turkey, 14 - 17 October 2015

STUDY OF THE IMPACT OF CHARLSON COMORBIDITY INDEX ON THE EFFICACY OF ADJUVANT TRASTUZUMAB IN PATIENTS WITH HER 2 POSITIVE EARLY BREAST CANCER

ŞENDUR M. A. N., AKSOY S., SILAY K., ÖZDEMİR N., OZAN Y., AKINCI M. B., et al.

18TH ECCO-40TH ESMO 2015, 25 - 29 September 2015 Sustainable Development

THE EFFECT OF INTERNATIONAL PROGNOSTIC INDEX IPI IN THEDETERMINATION OF PROGNOSIS OF EARLY STAGE DIFFUSE LARGE B CELLNON HODGKIN LYMPHOMA IS IT ENOUGH

ÖZDEMİR N., YAZICI O., HOCAZADE C., BOZKAYA Y., ŞENDUR M. A. N., AKINCI M. B., et al.

18TH ECCO-40TH ESMO 2015, 25 - 29 September 2015

Study of the impact of Charlson comorbidity index on the ef cacy of adjuvant trastuzumab in patients with HER2 positive early breast cancer

ŞENDUR M. A. N., AKSOY S., SILAY K., ÖZDEMİR N., YAZICI o., AKINCI M. B., et al.

18th ECCO-40th ESMO European Cancer Congress 25-29 September 2015, Vienna, Austria, European Journal of Cancer, Volume 51, Supplement 3, September 2015, S322, 25 - 29 September 2015 Sustainable Development

The importance of thiol disulphide homeostasis in patients with advanced gastric cancer AGC receiving modi ed docetaxel and cisplatin plus uorouracil mDCF regimen

Yazıcı O., ÖZDEMİR N., EREL Ö., Demirci N. S., AKSOY S., ŞENDUR M. A. N., et al.

18th ECCO-40th ESMO European Cancer Congress 25-29 September 2015, Vienna, Austria, European Journal of Cancer, Volume 51, Supplement 3, September 2015, S468., 25 - 29 September 2015 Sustainable Development